Wikisage, the free encyclopedia of the second generation, is digital heritage
Bezafibrate: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 4: | Line 4: | ||
<ref>[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4599574/ Systematic review and meta-analysis: bezafibrate in patients with primary biliary cirrhosis]</ref> | <ref>[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4599574/ Systematic review and meta-analysis: bezafibrate in patients with primary biliary cirrhosis]</ref> | ||
<ref>[http://www.impactjournals.com/oncotarget/misc/linkedout.php?pii=4528 Optimal drug regimens for primary biliary cirrhosis: a systematic review and network meta-analysis]</ref> | <ref>[http://www.impactjournals.com/oncotarget/misc/linkedout.php?pii=4528 Optimal drug regimens for primary biliary cirrhosis: a systematic review and network meta-analysis]</ref> | ||
ursodeoxycholic acid and bezafibrate are under stody in the treatment of biliar cyrrhosis (See Figure) | |||
<references/> | <references/> | ||
Revision as of 00:10, 5 November 2015
Bezafibrate was originally developed as a drug for treatment of hyperlipidemia and used for the prevention of cardiovascular diseases
ursodeoxycholic acid and bezafibrate are under stody in the treatment of biliar cyrrhosis (See Figure)